全文获取类型
收费全文 | 45009篇 |
免费 | 2105篇 |
国内免费 | 371篇 |
专业分类
耳鼻咽喉 | 468篇 |
儿科学 | 816篇 |
妇产科学 | 1300篇 |
基础医学 | 5333篇 |
口腔科学 | 1710篇 |
临床医学 | 3456篇 |
内科学 | 12593篇 |
皮肤病学 | 925篇 |
神经病学 | 3933篇 |
特种医学 | 1187篇 |
外科学 | 6818篇 |
综合类 | 170篇 |
一般理论 | 9篇 |
预防医学 | 2457篇 |
眼科学 | 716篇 |
药学 | 2434篇 |
中国医学 | 114篇 |
肿瘤学 | 3046篇 |
出版年
2024年 | 40篇 |
2023年 | 322篇 |
2022年 | 775篇 |
2021年 | 1464篇 |
2020年 | 789篇 |
2019年 | 1119篇 |
2018年 | 1548篇 |
2017年 | 1016篇 |
2016年 | 1109篇 |
2015年 | 1305篇 |
2014年 | 1792篇 |
2013年 | 2357篇 |
2012年 | 3614篇 |
2011年 | 3568篇 |
2010年 | 2011篇 |
2009年 | 1747篇 |
2008年 | 3035篇 |
2007年 | 3149篇 |
2006年 | 2939篇 |
2005年 | 2909篇 |
2004年 | 2622篇 |
2003年 | 2350篇 |
2002年 | 2079篇 |
2001年 | 272篇 |
2000年 | 187篇 |
1999年 | 289篇 |
1998年 | 366篇 |
1997年 | 322篇 |
1996年 | 283篇 |
1995年 | 279篇 |
1994年 | 219篇 |
1993年 | 164篇 |
1992年 | 140篇 |
1991年 | 100篇 |
1990年 | 102篇 |
1989年 | 84篇 |
1988年 | 65篇 |
1987年 | 57篇 |
1986年 | 73篇 |
1985年 | 70篇 |
1984年 | 73篇 |
1983年 | 65篇 |
1982年 | 94篇 |
1981年 | 66篇 |
1980年 | 71篇 |
1979年 | 39篇 |
1978年 | 47篇 |
1977年 | 37篇 |
1976年 | 35篇 |
1974年 | 29篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Marcia Carneiro VALERA Lilian Eiko MAEKAWA Luciane Dias de OLIVEIRA Antonio Olavo Cardoso JORGE érika SHYGEI Cláudio Antonio Talge CARVALHO 《Journal of applied oral science : revista FOB》2013,21(2):118-123
Objective:
The aim of this study was to evaluate the antimicrobial activity of auxiliary chemical substances and natural extracts on Candida albicans and Enterococcus faecalis inoculated in root canals.Material and Methods:
Seventy-two human tooth roots were contaminated with C. albicans and E. faecalis for 21 days. The groups were divided according to the auxiliary chemical substance into: G1) 2.5% sodium hypochlorite (NaOCl), G2) 2% chlorhexidine gel (CHX), G3) castor oil, G4) glycolic Aloe vera extract, G5) glycolic ginger extract, and G6) sterile saline (control). The samples of the root canal were collected at different intervals: confirmation collection, at 21 days after contamination; 1st collection, after instrumentation; and 2nd collection, seven days after instrumentation. Microbiological samples were grown in culture medium and incubated at 37º C for 48 hours.Results:
The results were submitted to the Kruskal-Wallis and Dunn (5%) statistical tests. NaOCl and CHX completely eliminated the microorganisms of the root canals. Castor oil and ginger significantly reduced the number of CFU of the tested bacteria. Reduction of CFU/mL at the 1st and 2nd collections for groups G1, G2, G3 and G4 was greater in comparison to groups G5 and G6.Conclusion:
It was concluded that 2.5% sodium hypochlorite and 2% chlorhexidine gel were more effective in eliminating C. albicans and E. faecalis, followed by the castor oil and glycolic ginger extract. The Aloe vera extract showed no antimicrobial activity. 相似文献993.
Jacqueline A. French Gregory L. Krauss Bernhard J. Steinhoff David Squillacote Haichen Yang Dinesh Kumar Antonio Laurenza 《Epilepsia》2013,54(1):117-125
Purpose: To assess the efficacy and safety of once‐daily doses of perampanel 8 and 12 mg when added to 1–3 concomitantly administered, approved antiepileptic drugs (AEDs) in patients with uncontrolled partial‐onset seizures. Methods: Study 305 was a multicenter, double‐blind, placebo‐controlled trial in patients aged 12 years and older with ongoing seizures despite prior therapy with at least two AEDs, and currently receiving 1–3 AEDs. Equal randomization to once‐daily oral perampanel 8 or 12 mg, or placebo was performed. Patients entered a 19‐week double‐blind treatment phase comprising a 6‐week titration period, with weekly 2‐mg dose increments, followed by a 13‐week maintenance period. Primary efficacy end points were the responder rate (proportion of patients who had a ≥50% reduction in seizure frequency during treatment per 28 days relative to baseline), and the percent change in seizure frequency per 28 days relative to pre‐perampanel baseline. A secondary end point was percent change in the frequency of complex partial plus secondarily generalized seizures. Adverse events (AEs) were monitored throughout the study. Key Findings: Three hundred eighty‐six patients were randomized and treated with study medication. Of these, 321 patients completed the study. The 50% responder rates (intent‐to‐treat analysis) were 14.7%, 33.3%, and 33.9%, respectively, for placebo, perampanel 8 mg, and perampanel 12 mg, with significant improvements over placebo for both perampanel 8 mg (p = 0.002) and 12 mg (p < 0.001). The median percent change from baseline in seizure frequency per 28 days (intent‐to‐treat analysis) was ?9.7%, ?30.5%, and ?17.6% for placebo, 8 mg, and 12 mg, respectively, with significant reductions compared with placebo for both 8 mg (p < 0.001) and 12 mg (p = 0.011). For complex partial seizures plus partial seizures that secondarily generalized, the median percent change in frequency was ?32.7% (8 mg), ?21.9 (12 mg), and ?8.1% (placebo), with significant reductions for both 8 mg (p < 0.001) and 12 mg (p = 0.005). The most frequent (occurring in ≥10% of patients in any treatment group) treatment‐emergent AEs were dizziness, somnolence, fatigue, and headache, with an apparent dose effect suggested for all except headache. Significance: This phase III trial demonstrated that adjunctive treatment with once‐daily perampanel at 8 mg and 12 mg was effective in improving seizure control in patients 12 years and older with refractory partial‐onset seizures. These study results also demonstrated that once‐daily doses of 8 mg and 12 mg were safe and acceptably tolerated in this study. Perampanel demonstrated a favorable risk/benefit ratio in this population. 相似文献
994.
Gregory L. Krauss Emilio Perucca Elinor Ben‐Menachem Patrick Kwan Jerry J. Shih David Squillacote Haichen Yang Michelle Gee Jin Zhu Antonio Laurenza 《Epilepsia》2013,54(1):126-134
Purpose: To evaluate safety, tolerability, and seizure outcome data during long‐term treatment with once‐daily adjunctive perampanel (up to 12 mg/day) in patients with refractory partial‐onset seizures. Methods: Study 307 was an extension study for patients completing the double‐blind phase of three pivotal phase III trials (studies 304, 305, and 306). The study consisted of two phases: an open‐label treatment phase (including a 16‐week blinded conversion period and a planned 256‐week maintenance period) and a 4‐week follow‐up phase. Patients were blindly titrated during the conversion period to their individual maximum tolerated dose (maximum 12 mg/day). Adverse events (AEs) were monitored throughout the study and seizure frequency recorded. The interim data cutoff date for analyses was December 1, 2010. Key Findings: In total, 1,218 patients were enrolled in the study. At the interim cutoff date, 1,186 patients were in the safety analysis set; 1,089 (91.8%) patients had >16 weeks of exposure to perampanel, 580 (48.9%) patients had >1 year of exposure, and 19 (1.6%) patients had >2 years of exposure. At the interim analysis, 840 (70.8%) patients remained on perampanel treatment. The large majority of patients (n = 1,084 [91%]) were titrated to 10 mg or 12 mg/day. Median (range) duration of exposure was 51.4 (1.1–128.1) weeks. Treatment‐emergent AEs were reported in 87.4% of patients. The most frequent were dizziness (43.9%), somnolence (20.2%), headache (16.7%), and fatigue (12.1%). Serious AEs were reported in 13.2% of patients. In the intent‐to‐treat analysis set (n = 1,207), the frequency of all seizures decreased over the first 26 weeks of perampanel treatment in patients with at least 26 weeks of exposure to perampanel (n = 1,006 [83.3%]); this reduction was maintained in patients with at least 1 year of exposure (n = 588 [48.7%]). The overall median percent changes in seizure frequency in patients included in each 13‐week interval of perampanel treatment were ?39.2% for weeks 14–26 (n = 1,114), ?46.5% for weeks 40–52 (n = 731), and ?58.1% for weeks 92–104 (n = 59). Overall responder rates in patients included in each 13‐week interval of perampanel treatment were 41.4% for weeks 14–26 (n = 1,114), 46.9% for weeks 40–52 (n = 731), and 62.7% for weeks 92–104 (n = 59). During the blinded conversion period, the reduction in seizure frequency in patients previously randomized to placebo (?42.4%, n = 369) was similar to that in patients previously randomized to perampanel (?41.5%, n = 817). Significance: Consistent with pivotal phase III trials, these interim results demonstrated that perampanel had a favorable tolerability profile in patients with refractory partial‐onset seizures over the longer term. The decrease in seizure frequency was consistent and maintained in those patients over at least 1 year of perampanel exposure. 相似文献
995.
996.
María Teresa Julián Jose María Balibrea María Luisa Granada Pau Moreno Antonio Alastrué Manel Puig-Domingo Anna Lucas 《American journal of surgery》2013
Background
There is no consensus about the usefulness of postoperative intact parathyroid hormone (iPTH) determination to predict permanent hypoparathyroidism (pHPP). We evaluated the value of calcium (Ca2+) and iPTH concentration at 24 hours after total thyroidectomy (TT) for predicting pHPP.Methods
Ca2+ and iPTH levels from 70 consecutive patients who underwent TT were measured at 24 hours and 6 months after TT.Results
Five patients (7.1%) developed pHPP. An iPTH concentration ≤5.8 pg/mL at 24 hours after TT identified patients at risk for pHPP (sensitivity, 100%; specificity, 81.5%), but it was not accurate enough to predict its development (positive predictive value, 30%). Conversely, an iPTH level >5.8 pg/mL predicted normal parathyroid function at 6 months (negative predictive value, 100%). Compared with iPTH, a postoperative Ca2+ level ≤1.95 mmol/L was 60% sensitive and 78.5% specific to predict pHPP.Conclusions
An iPTH concentration >5.8 pg/mL on the first postoperative day rules out pHPP with much better diagnostic accuracy than Ca2+. Postoperative iPTH could be helpful in identifying patients at risk for developing pHPP. 相似文献997.
998.
999.
Clara Isabel Bayarri Lara Sebastián Sevilla López Abel Sánchez-Palencia Ramos Amira Alkourdi Martínez Francisco Hernández Escobar Florencio Quero Valenzuela Francisco Javier Ruiz Zafra Antonio Cueto Ladrón de Guevara 《Cirugía espa?ola》2013
Introduction
Descending necrotizing mediastinitis (DNM) is a serious infection which occurs as a complication of oropharyngeal infection. Its surgical management and the routine transthoracic approach remain controversial. In this article we report our experience in the management of this disease, and review the different surgical approaches that have been reported in the medical literature.Material and methods
A retrospective review was made of the clinical records of 29 patients treated between 1988 and 2009. Several demographic variables were analyzed, origin of the initial infection, stage of the disease according to Endo's classification, surgical technique and outcome.Results
Surgical treatment consisted of both cervical and mediastinal drainage and radical debridement. The mediastinal drainage was made through a transcervical approach in 10 cases and transthoracic in 19, depending on the extent of the mediastinitis. The outcome was satisfactory in 24 patients and 5 died (mortality 17.2%).Conclusions
According to our results and the conclusions of the main authors, we recommend a prompt and aggressive surgery with a transthoracic approach in cases of widespread DNM. 相似文献1000.